Literature DB >> 24294514

A case report of trastuzumab dose in gastric cancer.

Chrisann Kyi1, Manish A Shah.   

Abstract

INTRODUCTION: Trastuzumab (Herceptin®, F. Hoffman-La Roche) is now approved for the treatment of metastatic HER2-positive gastric cancer based on the improved survival observed on the phase III Trastuzumab for Gastric Adenocarcinoma (ToGA) study. Standard dosing of trastuzumab is currently extrapolated from breast cancer data: a 3-week schedule (8 mg/kg load, 6 mg/kg q 3 weeks) or a weekly schedule (4 mg/kg load, 2 mg/kg q week). CASE STUDY: Our case study examines an HER2-positive metastatic gastric cancer patient that required a higher than currently recommended standard dose of trastuzumab to achieve treatment response. DISCUSSION: Several mechanisms may explain these findings and include higher clearance of trastuzumab, higher tumor burden, and pharmacologic resistance in metastatic gastric cancer versus breast cancer. The question of trastuzumab dosing in gastric cancer is currently being evaluated in a phase III clinical trial.

Entities:  

Keywords:  Trastuzumab; metastatic gastric cancer; pharmacokinetics

Year:  2013        PMID： 24294514      PMCID： PMC3819770          DOI： 10.3978/j.issn.2078-6891.2013.015

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN： 2078-6891


  13 in total

1.  Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.

Authors:  Charles L Vogel; Melody A Cobleigh; Debu Tripathy; John C Gutheil; Lyndsay N Harris; Louis Fehrenbacher; Dennis J Slamon; Maureen Murphy; William F Novotny; Michael Burchmore; Steven Shak; Stanford J Stewart; Michael Press
Journal:  J Clin Oncol       Date:  2002-02-01       Impact factor: 44.544

2.  Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.

Authors:  J Baselga; D Tripathy; J Mendelsohn; S Baughman; C C Benz; L Dantis; N T Sklarin; A D Seidman; C A Hudis; J Moore; P P Rosen; T Twaddell; I C Henderson; L Norton
Journal:  J Clin Oncol       Date:  1996-03       Impact factor: 44.544

3.  Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer.

Authors:  Rene Bruno; Carla B Washington; Jian-Feng Lu; Grazyna Lieberman; Ludger Banken; Pamela Klein
Journal:  Cancer Chemother Pharmacol       Date:  2005-05-03       Impact factor: 3.333

4.  Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.

Authors:  M A Cobleigh; C L Vogel; D Tripathy; N J Robert; S Scholl; L Fehrenbacher; J M Wolter; V Paton; S Shak; G Lieberman; D J Slamon
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

5.  Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel.

Authors:  Brian Leyland-Jones; Karen Gelmon; Jean-Pierre Ayoub; Andrew Arnold; Shail Verma; Reg Dias; Parviz Ghahramani
Journal:  J Clin Oncol       Date:  2003-09-24       Impact factor: 44.544

6.  Assessment of a HER2 scoring system for gastric cancer: results from a validation study.

Authors:  M Hofmann; O Stoss; D Shi; R Büttner; M van de Vijver; W Kim; A Ochiai; J Rüschoff; T Henkel
Journal:  Histopathology       Date:  2008-04-18       Impact factor: 5.087

Review 7.  Trastuzumab and antiestrogen therapy: focus on mechanisms of action and resistance.

Authors:  Alberto Ocaña; Juan J Cruz; Atanasio Pandiella
Journal:  Am J Clin Oncol       Date:  2006-02       Impact factor: 2.339

8.  Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency.

Authors:  Chien-Hsing Lu; Shannon L Wyszomierski; Ling-Ming Tseng; Meng-Hong Sun; Keng-Hsueh Lan; Christopher L Neal; Gordon B Mills; Gabriel N Hortobagyi; Francisco J Esteva; Dihua Yu
Journal:  Clin Cancer Res       Date:  2007-10-01       Impact factor: 12.531

9.  Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

Authors:  Maurizio Scaltriti; Federico Rojo; Alberto Ocaña; Judit Anido; Marta Guzman; Javier Cortes; Serena Di Cosimo; Xavier Matias-Guiu; Santiago Ramon y Cajal; Joaquin Arribas; José Baselga
Journal:  J Natl Cancer Inst       Date:  2007-04-18       Impact factor: 13.506

Review 10.  Trastuzumab for gastric cancer.

Authors:  Judith Meza-Junco; Heather-Jane Au; Michael B Sawyer
Journal:  Expert Opin Biol Ther       Date:  2009-12       Impact factor: 4.388
View more
  3 in total

1.  Proteomic characterization of gastric cancer response to chemotherapy and targeted therapy reveals new therapeutic strategies.

Authors:  Yan Li; Chen Xu; Bing Wang; Fujiang Xu; Fahan Ma; Yuanyuan Qu; Dongxian Jiang; Kai Li; Jinwen Feng; Sha Tian; Xiaohui Wu; Yunzhi Wang; Yang Liu; Zhaoyu Qin; Yalan Liu; Jing Qin; Qi Song; Xiaolei Zhang; Akesu Sujie; Jie Huang; Tianshu Liu; Kuntang Shen; Jian-Yuan Zhao; Yingyong Hou; Chen Ding
Journal:  Nat Commun       Date:  2022-09-29       Impact factor: 17.694

2.  Targeted therapy in gastroesophageal cancers: past, present and future.

Authors:  Janghee Woo; Stacey A Cohen; Jonathan E Grim
Journal:  Gastroenterol Rep (Oxf)       Date:  2015-10-27

3.  Xeloda Oral, Trastuzumab, and Pertuzumab Combined Drug Therapy Reduced Cervical Lymphadenopathy and Dermal Involvement in Patient With Recurrent Breast Cancer: Case Report.

Authors:  Victor Manuel Saure Sarría; Ariel D Arencibia; Vívian D'Afonseca
Journal:  J Investig Med High Impact Case Rep       Date:  2020 Jan-Dec
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.